

Fill in this information to identify the case:

United States Bankruptcy Court for the:

DISTRICT OF DELAWARE

Case number (if known) Chapter 11

☐ Check if this is an amended filing

Official Form 201

Voluntary Petition for Non-Individuals Filing for Bankruptcy

04/25

If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and the case number (if known). For more information, a separate document, *Instructions for Bankruptcy Forms for Non-Individuals*, is available.

1. Debtor's name Apertor Pharmaceuticals, Inc.

2. All other names debtor used in the last 8 years

Include any assumed names, trade names and doing business as names

3. Debtor's federal Employer Identification Number (EIN) 85-3493161

4. Debtor's address Principal place of business Mailing address, if different from principal place of business

651 Gateway Blvd, Suite 1600
South San Francisco, CA 94080

Number, Street, City, State & ZIP Code

San Mateo

County

P.O. Box, Number, Street, City, State & ZIP Code

Location of principal assets, if different from principal place of business

Number, Street, City, State & ZIP Code

5. Debtor's website (URL) https://apertorpharma.com/

6. Type of debtor
☒ Corporation (including Limited Liability Company (LLC) and Limited Liability Partnership (LLP))
☐ Partnership (excluding LLP)
☐ Other. Specify:



251220125121500000000001

Debtor **Apertor Pharmaceuticals, Inc.**
Name

Case number (if known)

7. Describe debtor's business A. *Check one:*

- ☐ Health Care Business (as defined in 11 U.S.C. § 101(27A))
- ☐ Single Asset Real Estate (as defined in 11 U.S.C. § 101(51B))
- ☐ Railroad (as defined in 11 U.S.C. § 101(44))
- ☐ Stockbroker (as defined in 11 U.S.C. § 101(53A))
- ☐ Commodity Broker (as defined in 11 U.S.C. § 101(6))
- ☐ Clearing Bank (as defined in 11 U.S.C. § 781(3))
- ☒ None of the above

B. *Check all that apply*

- ☐ Tax-exempt entity (as described in 26 U.S.C. §501)
- ☐ Investment company, including hedge fund or pooled investment vehicle (as defined in 15 U.S.C. §80a-3)
- ☐ Investment advisor (as defined in 15 U.S.C. §80b-2(a)(11))

C. NAICS (North American Industry Classification System) 4-digit code that best describes debtor. See <http://www.uscourts.gov/four-digit-national-association-naics-codes>.

5417**8. Under which chapter of the Bankruptcy Code is the debtor filing?***Check one:*

- ☐ Chapter 7
- ☐ Chapter 9

☒ Chapter 11. *Check all that apply:*

- ☐ Debtor's aggregate noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than \$3,424,000 (amount subject to adjustment on 4/01/28 and every 3 years after that).
- ☐ The debtor is a small business debtor as defined in 11 U.S.C. § 101(51D). If the debtor is a small business debtor, attach the most recent balance sheet, statement of operations, cash-flow statement, and federal income tax return or if all of these documents do not exist, follow the procedure in 11 U.S.C. § 1116(1)(B).
- ☐ The debtor is a small business debtor as defined in 11 U.S.C. § 101(51D), and it chooses to proceed under Subchapter V of Chapter 11.
- ☐ A plan is being filed with this petition.
- ☐ Acceptances of the plan were solicited prepetition from one or more classes of creditors, in accordance with 11 U.S.C. § 1126(b).
- ☐ The debtor is required to file periodic reports (for example, 10K and 10Q) with the Securities and Exchange Commission according to § 13 or 15(d) of the Securities Exchange Act of 1934. File the *Attachment to Voluntary Petition for Non-Individuals Filing for Bankruptcy under Chapter 11* (Official Form 201A) with this form.
- ☐ The debtor is a shell company as defined in the Securities Exchange Act of 1934 Rule 12b-2.

☐ Chapter 12**9. Were prior bankruptcy cases filed by or against the debtor within the last 8 years?**

- ☒ No.
- ☐ Yes.

If more than 2 cases, attach a separate list.

District _____

District _____

When _____

When _____

Case number _____

Case number _____

10. Are any bankruptcy cases pending or being filed by a business partner or an affiliate of the debtor?

- ☐ No
- ☒ Yes.

Debtor Apertor Pharmaceuticals, Inc. Case number (if known) _____
NameList all cases. If more than 1,
attach a separate listDebtor **See Attachment**Relationship _____
District _____ When _____ Case number, if known _____**11. Why is the case filed in this district?**

Check all that apply:

- ☒ Debtor has had its domicile, principal place of business, or principal assets in this district for 180 days immediately preceding the date of this petition or for a longer part of such 180 days than in any other district.
- ☒ A bankruptcy case concerning debtor's affiliate, general partner, or partnership is pending in this district.

12. Does the debtor own or have possession of any real property or personal property that needs immediate attention?☒ No☐ Yes. Answer below for each property that needs immediate attention. Attach additional sheets if needed.**Why does the property need immediate attention?** (Check all that apply.)☐ It poses or is alleged to pose a threat of imminent and identifiable hazard to public health or safety.

What is the hazard? _____

☐ It needs to be physically secured or protected from the weather.☐ It includes perishable goods or assets that could quickly deteriorate or lose value without attention (for example, livestock, seasonal goods, meat, dairy, produce, or securities-related assets or other options).☐ Other _____**Where is the property?** _____

Number, Street, City, State & ZIP Code _____

Is the property insured?☐ No☐ Yes. Insurance agency _____

Contact name _____

Phone _____

Statistical and administrative information**13. Debtor's estimation of available funds**

Check one:

- ☒ Funds will be available for distribution to unsecured creditors.
- ☐ After any administrative expenses are paid, no funds will be available to unsecured creditors.

14. Estimated number of creditors☐ 1-49☒ 50-99☐ 100-199☐ 200-999☐ 1,000-5,000☐ 5001-10,000☐ 10,001-25,000☐ 25,001-50,000☐ 50,001-100,000☐ More than 100,000**15. Estimated Assets**☐ \$0 - \$50,000☐ \$50,001 - \$100,000☐ \$100,001 - \$500,000☐ \$500,001 - \$1 million☐ \$1,000,001 - \$10 million☒ \$10,000,001 - \$50 million☐ \$50,000,001 - \$100 million☐ \$100,000,001 - \$500 million☐ \$500,000,001 - \$1 billion☐ \$1,000,000,001 - \$10 billion☐ \$10,000,000,001 - \$50 billion☐ More than \$50 billion**16. Estimated liabilities**☐ \$0 - \$50,000☐ \$50,001 - \$100,000☐ \$100,001 - \$500,000☐ \$500,001 - \$1 million☒ \$1,000,001 - \$10 million☐ \$10,000,001 - \$50 million☐ \$50,000,001 - \$100 million☐ \$100,000,001 - \$500 million☐ \$500,000,001 - \$1 billion☐ \$1,000,000,001 - \$10 billion☐ \$10,000,000,001 - \$50 billion☐ More than \$50 billion

Debtor

Apertor Pharmaceuticals, Inc.

Name

Case number (if known)

Request for Relief, Declaration, and Signatures

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

**17. Declaration and signature
of authorized
representative of debtor**

The debtor requests relief in accordance with the chapter of title 11, United States Code, specified in this petition.

I have been authorized to file this petition on behalf of the debtor.

I have examined the information in this petition and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 12/15/2025

MM / DD / YYYY

X /s/ Edmund Graziani

Signature of authorized representative of debtor

Edmund Graziani

Printed name

Title **CEO**

18. Signature of attorney

X /s/ L. Katherine Good

Signature of attorney for debtor

Date 12/15/2025

MM / DD / YYYY

L. Katherine Good

Printed name

Potter Anderson & Corroon LLP

Firm name

1313 North Market Street

6th Floor

Wilmington, DE 19801

Number, Street, City, State & ZIP Code

Contact phone 302-984-6000

Email address kgood@potteranderson.com

5101 DE

Bar number and State

Debtor **Apertor Pharmaceuticals, Inc.** Case number (if known) _____
 Name

Fill in this information to identify the case:

United States Bankruptcy Court for the:

DISTRICT OF DELAWARE

Case number (if known) _____ Chapter **11**

☐ Check if this is an amended filing

FORM 201. VOLUNTARY PETITION
Pending Bankruptcy Cases Attachment

Debtor	Apple Tree Life Sciences, Inc.	Relationship to you	Affiliate
District	Delaware	When 12/09/25	Case number, if known 25-12177
Debtor	ATP III GP, Ltd.	Relationship to you	Affiliate
District	Delaware	When 12/09/25	Case number, if known 25-12179
Debtor	ATP Life Science Ventures, L.P.	Relationship to you	Affiliate
District	Delaware	When 12/09/25	Case number, if known 25-12178
Debtor	Initial Therapeutics, Inc.	Relationship to you	Affiliate
District	Delaware	When 12/15/25	Case number, if known
Debtor	Marlinspike Therapeutics, Inc.	Relationship to you	Affiliate
District	Delaware	When 12/15/25	Case number, if known
Debtor	Red Queen Therapeutics, Inc.	Relationship to you	Affiliate
District	Delaware	When 12/15/25	Case number, if known

**Written Consent
In Lieu Of Meeting of
The Board of Directors of Apertor Pharmaceuticals, Inc.,**

December 12, 2025

**APPROVAL FOR FILING OF VOLUNTARY PETITION FOR RELIEF UNDER
CHAPTER 11, APPOINTMENT OF CRO, AND RETENTION OF PROFESSIONALS**

The undersigned, being all of the directors (the “Directors”) of Apertor Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), do hereby consent to the adoption of the following resolutions:

WHEREAS, the Directors have considered certain materials presented by, or on behalf of, the Corporation’s management (“Management”) and its advisors (collectively, “Advisors”), including, but not limited to, materials regarding the liabilities, obligations and liquidity of the Corporation, the strategic alternatives available to the Corporation, and the impact of the foregoing on the Corporation’s business;

WHEREAS, the Directors have had adequate opportunity to consult with Management and the Advisors regarding the materials presented, to obtain additional information and to fully consider each of the strategic alternatives available to the Corporation;

WHEREAS, the Directors have determined in the exercise of their business judgment that it is advisable and in the best interests of the Corporation and its stakeholders to appoint a Chief Restructuring Officer of the Corporation, vested with such powers and to perform such duties as the Directors by resolution may delegate to him from time to time;

WHEREAS, the Directors have determined in the exercise of their business judgment that it is advisable and in the best interests of the Corporation to retain B. Riley to act as financial advisor to the Corporation and provide the Corporation with restructuring advisors and support personnel, including, without limitation, Perry Mandarino, Senior Managing Director of B. Riley, as Chief Restructuring Officer (the “CRO”), to represent the Corporation in carrying out its duties under the Bankruptcy Code;

WHEREAS, the Directors have determined in the exercise of their business judgment that it is advisable and in the best interests of the Corporation to appoint the law firm of Quinn Emanuel Urquhart & Sullivan, LLP as general bankruptcy co-counsel of the Corporation;

WHEREAS, the Directors have determined in the exercise of their business judgment that it is advisable and in the best interests of the Corporation to appoint the law firm of Potter Anderson & Corroon LLP, as general bankruptcy co-counsel.

WHEREAS, the Directors have determined in the exercise of their business judgment that it is advisable and in the best interests of the Corporation to appoint the law firm of Murphy & King, Professional Corporation as general bankruptcy co-counsel.

WHEREAS, the Directors have determined, in the judgment of the Directors, that the following resolutions are advisable and in the best interests of the Corporation, its stakeholders, its creditors, and other parties in interest.

NOW THEREFORE, in consideration of the preceding recitals, **BE IT RESOLVED**, that in the judgment of the Directors, it is desirable and in the best interest of the Corporation, its stakeholders, its creditors, and other parties in interest, that the Corporation shall be, and hereby is, in all respects authorized to file, or cause to be filed, a voluntary petition for relief (a “Bankruptcy Petition”) commencing a case (the “Chapter 11 Case”) under the provisions of chapter 11 of title 11 of the United States Code, 11 U.S.C. § 101 *et seq.* (as amended, the “Bankruptcy Code”) for the Corporation, and the Directors hereby consent to, authorize, and approve, the filing of such Bankruptcy Petition; and be it hereby

FURTHER RESOLVED, that, effective as of December 12, 2025, Mr. Mandarin, Senior Managing Director of B. Riley, be, and hereby is, appointed Chief Restructuring Officer of the Corporation, vested with such powers and to perform such duties as the Directors by resolution may delegate from time to time, shall report to, and take direction from, the Directors, and shall serve as Chief Restructuring Officer until their removal by resolution of the Directors or his resignation; and be it hereby

FURTHER RESOLVED, that if Mr. Mandarin expressly delegates specific duties within his powers to a specific officer of the Corporation, in which case such officer shall report to Mr. Mandarin and take direction from Mr. Mandarin or the Directors with respect to such delegated duties; and be it hereby

FURTHER RESOLVED, that Mr. Mandarin shall continue to be employed by B. Riley and shall be permitted to perform and undertake such other activities unrelated to the Corporation as required by his employment with B. Riley; and be it hereby

FURTHER RESOLVED, that Mr. Mandarin, the Corporation’s Chief Restructuring Officer, and any duly appointed officer of the Corporation, acting individually and with full power of substitution (together with any persons to whom such person delegates certain responsibilities, collectively, the “Authorized Persons”) be, and hereby is, authorized to execute and file on behalf of the Corporation all petitions, schedules, lists, and other motions, papers, or documents, and to take any and all action that such Authorized Person deems necessary or proper to obtain such relief, including, but not limited to, any action necessary or proper to maintain the ordinary course operations of the Corporation; and be it hereby

FURTHER RESOLVED, that each of the Authorized Persons, acting individually and with full power of substitution, be, and hereby is, authorized, empowered and directed to employ the following professionals on behalf of the Corporation: (i) the law firm of Quinn Emanuel Urquhart & Sullivan LLP, as general bankruptcy co-counsel, (ii) the law firm of Potter Anderson & Corroon LLP, as general bankruptcy co-counsel, (iii) the firm of B. Riley, as a restructuring advisor, (iv) the law firm of Murphy & King, Professional Corporation, as general bankruptcy

co-counsel, and (v) any other legal counsel, accountants, financial advisors, restructuring advisors or other professionals such Authorized Person deems necessary, appropriate or advisable; each to represent and assist the Corporation in carrying out its duties and responsibilities and exercising its rights under the Bankruptcy Code and any applicable law (including, but not limited to, the law firm filing any pleadings or responses) and to take any and all actions to advance the rights and obligations of the Corporation, including filing any motions, objections, replies, applications, or pleadings; and in connection therewith, each of the Authorized Persons be, and hereby is authorized, empowered and directed, in accordance with the terms and conditions hereof, to execute appropriate retention agreements, pay appropriate retainers, and to cause to be filed appropriate applications for authority to retain such services.

GENERAL AUTHORIZATION

BE IT HEREBY FURTHER RESOLVED, that each of the Authorized Persons, each acting individually and with full power of substitution be, and hereby is, authorized, empowered and directed to execute and file all petitions, schedules, motions, lists, applications, pleadings, and other papers, and to perform such further actions and execute such further documentation that such Authorized Person in his/her/its/their absolute discretion deems necessary, appropriate or desirable in accordance with these resolutions and the Chapter 11 Case, with a view to the successful prosecution of such case; and be it hereby

FURTHER RESOLVED, that the officers and/or Authorized Persons of the Corporation be, and hereby are, authorized to undertake all acts necessary and proper to carry out the full implementation and execution of the aforesaid resolutions, including, but not limited to (i) the negotiation of agreements, amendments, supplements, instruments or certificates not now known but which may be required; (ii) the negotiation of changes and additions to any agreements, amendments, supplements, instruments or certificates currently existing; (iii) the execution, delivery and filing (if applicable) of any of the foregoing; (iv) the execution of powers of attorney to authorize attorneys-in-fact to act on their behalf; and (v) the payment of all fees, liabilities, taxes and other expenses as the officers and/or Authorized Persons, in their sole discretion, may approve or deem necessary, appropriate or advisable in order to carry out the intent and accomplish the purposes of the foregoing resolutions, with all such actions, executions, deliveries, filings and payments to be conclusive evidence of the officers' and/or Authorized Persons' authority and the Directors' approval thereof; and be it hereby


FURTHER RESOLVED, that the Directors have received sufficient notice of the actions and transactions relating to the matters contemplated by the foregoing resolutions, as may be required by the organizational documents of the Corporation, or hereby waive any right to have received such notice.

FURTHER RESOLVED, that all actions taken before or after the date of adoption of the foregoing resolutions by any of the Corporation, the Chief Restructuring Officer, and the Corporation's officers that are within the authority conferred by these resolutions are hereby expressly ratified, confirmed, approved and adopted by the Directors as the acts and deeds of the Corporation in all respects and for all purposes, as if specifically set out in these resolutions; and be it hereby

FURTHER RESOLVED, that the Secretary and any other appropriate officer of the Corporation are, and each individually hereby is, authorized, empowered and directed to certify and furnish copies of these resolutions and such statements as to the incumbency of the Corporation's officers and/or Authorized Persons, under corporate seal if necessary, as may be requested, and any person receiving such certified copy is and shall be authorized to rely upon the contents thereof.

IN WITNESS WHEREOF, the undersigned have executed these resolutions as of the date above first written.

Apertor Pharmaceuticals, Inc.

By: 
Seth L. Harrison, Director

By: _____
Paul Da Silva Jardine, Director

By: _____
Spiros Liras, Director

By: _____
Edmund Graziani, Director

By: _____
Paul Eisenberg, Director

FURTHER RESOLVED, that the Secretary and any other appropriate officer of the Corporation are, and each individually hereby is, authorized, empowered and directed to certify and furnish copies of these resolutions and such statements as to the incumbency of the Corporation's officers and/or Authorized Persons, under corporate seal if necessary, as may be requested, and any person receiving such certified copy is and shall be authorized to rely upon the contents thereof.


IN WITNESS WHEREOF, the undersigned have executed these resolutions as of the date above first written.

Apertor Pharmaceuticals, Inc.

By: _____
Seth L. Harrison, Director

By: _____
Paul Da Silva Jardine, Director

By: _____
Spiros Liras, Director

By:  _____
Edmund Graziani, Director

By: _____
Paul Eisenberg, Director

FURTHER RESOLVED, that the Secretary and any other appropriate officer of the Corporation are, and each individually hereby is, authorized, empowered and directed to certify and furnish copies of these resolutions and such statements as to the incumbency of the Corporation's officers and/or Authorized Persons, under corporate seal if necessary, as may be requested, and any person receiving such certified copy is and shall be authorized to rely upon the contents thereof.

IN WITNESS WHEREOF, the undersigned have executed these resolutions as of the date above first written.

Apertor Pharmaceuticals, Inc.

By: _____
Seth L. Harrison, Director

By: _____
Paul Da Silva Jardine, Director

By:  _____
Spiros Liras, Director

By: _____
Edmund Graziani, Director


By: _____
Paul Eisenberg, Director

FURTHER RESOLVED, that the Secretary and any other appropriate officer of the Corporation are, and each individually hereby is, authorized, empowered and directed to certify and furnish copies of these resolutions and such statements as to the incumbency of the Corporation's officers and/or Authorized Persons, under corporate seal if necessary, as may be requested, and any person receiving such certified copy is and shall be authorized to rely upon the contents thereof.

IN WITNESS WHEREOF, the undersigned have executed these resolutions as of the date above first written.

Apertor Pharmaceuticals, Inc.

By: _____
Seth L. Harrison, Director

By:  _____
Paul Da Silva Jardine, Director

By: _____
Spiros Liras, Director

By: _____
Edmund Graziani, Director

By: _____
Paul Eisenberg, Director

FURTHER RESOLVED, that the Secretary and any other appropriate officer of the Corporation are, and each individually hereby is, authorized, empowered and directed to certify and furnish copies of these resolutions and such statements as to the incumbency of the Corporation's officers and/or Authorized Persons, under corporate seal if necessary, as may be requested, and any person receiving such certified copy is and shall be authorized to rely upon the contents thereof.

IN WITNESS WHEREOF, the undersigned have executed these resolutions as of the date above first written.


Apertor Pharmaceuticals, Inc.

By: _____
Seth L. Harrison, Director

By: _____
Paul Da Silva Jardine, Director

By: _____
Spiros Liras, Director

By: _____
Edmund Graziani, Director

By:  _____
Paul Eisenberg, Director

Fill in this information to identify the case:

Debtor name **Apertor Pharmaceuticals, Inc.**
 United States Bankruptcy Court for the: **DISTRICT OF DELAWARE**
 Case number (if known): _____

☐ Check if this is an
 amended filing

Official Form 204
Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders
12/15

A list of creditors holding the 20 largest unsecured claims must be filed in a Chapter 11 or Chapter 9 case. Include claims which the debtor disputes. Do not include claims by any person or entity who is an insider, as defined in 11 U.S.C. § 101(31). Also, do not include claims by secured creditors, unless the unsecured claim resulting from inadequate collateral value places the creditor among the holders of the 20 largest unsecured claims.

Name of creditor and complete mailing address, including zip code	Name, telephone number and email address of creditor contact	Nature of claim (for example, trade debts, bank loans, professional services, and government contracts)	Indicate if claim is contingent, unliquidated, or disputed	Amount of claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
				Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
1640 South Loop Road LLC c/o Paceline Investors LLC 242 California St San Francisco, CA 94111	ari.rokeach@nmrk.com	Office Space	Unliquidated			\$467,573.04
Alameda County Tax Collector 1221 Oak St Rm 131 Attn: Henry C. Levy Oakland, CA 94612	henry.levy@acgov.org	Taxes				\$28,059.10
Benchling, Inc. 680 Folsom Street San Francisco, CA 94107	ar@benchling.com	IT Software				\$15,000.00
BioDuro, LLC 11011 Torreyana Road Suite 100 San Diego, CA 92121	billing@bioduro.com	Professional Services - Scientific Research				\$9,850.00
BioProcure, Inc. 660 Main St Woburn, MA 01801	accounting@biopr ocure.com	Professional Services - Procurement				\$32,275.00
Browne Consulting Group 1 Broadway Fl 14 Cambridge, MA 02142	accounting@browneconsultinggroup.com	Professional Services - Accounting				\$39,263.75
Cell Signaling Technology, Inc. 3 Trask Lane Danvers, MA 01923	accountsreceivable@cellsignal.com	R&D Supplies				\$19,647.81

Debtor **Apertor Pharmaceuticals, Inc.**
Name

Case number (if known)

Name of creditor and complete mailing address, including zip code	Name, telephone number and email address of creditor contact	Nature of claim (for example, trade debts, bank loans, professional services,	Indicate if claim is contingent, unliquidated, or disputed	Amount of claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
				Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
Clarke Consulting, Inc. 8605 Santa Monica Boulevard #19613 Los Angeles, CA 90024	sales@clarkeconsulting.com	Professional Services - IT Support				\$12,375.00
CSC Leasing Company 6802 Paragon Place, Suite 350 Richmond, VA 23230	tabbott@cscleasing.com	Equipment Rental				\$41,560.00
De Lage Landen Financial Services, Inc. 1111 Old Eagle School Rd Wayne, PA 19087	cashapplication@leasedirect.com	Equipment Rental				\$59,876.70
Digital Insurance, LLC 200 Galleria Pkwy Ste1950 Atlanta, GA 30339	dibilling@onedigital.com	Professional Services - HR Consulting				\$35,736.52
Elsevier B.V. AR & Collections P.O. Box 7247-8455 Philadelphia, PA 19170	r.naudiyal@elsevier.com	IT Software				\$10,017.00
IQ Proteomics, LLC 39 Grant St #400 Framingham, MA 01702	brian_erickson@iqpromteomics.com	Professional Services - Scientific Research				\$13,240.00
Laboratory Equipment Company 2506 Technology Dr Hayward, CA 94545	labequipco.accounting@escalon.services	Equipment				\$18,392.15
Life Technologies Corporation 12088 Collections Center Dr. Chicago, IL 60693	accountsreceivableus@invitrogen.com	R&D Supplies				\$13,817.55
Reaction Biology Corporation One Great Valley Parkway Suite 2 Malvern, PA 19355	info@reactionbiology.com	R&D Supplies				\$9,529.00

Debtor **Apertor Pharmaceuticals, Inc.**
Name

Case number (if known)

Name of creditor and complete mailing address, including zip code	Name, telephone number and email address of creditor contact	Nature of claim (for example, trade debts, bank loans, professional services,	Indicate if claim is contingent, unliquidated, or disputed	Amount of claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
				Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
Science Suite Inc. dba BioRender 49 Spadina Ave Ste 200 Toronto, Canada M5V 2J1	ar@biorender.com	IT Software				\$13,739.00
University of North Carolina at Wilmingt 601 South College Road Wilmington, NC 28403	billing@uncw.edu	Professional Services - Scientific Research				\$43,944.25
Wilson Sonsini Goodrich & Rosati PC 650 Page Mill Road Palo Alto, CA 94304	finance@wsgr.com	Professional Services - Legal				\$135,006.45
Zhejiang Huida Biotech Co.,LTD. Floor 3, building 94, No. 700 Shixiang Road Hangzhou, China	wendy@huidabiotech.com	Professional Services - Scientific Research				\$80,400.00

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Apertor Pharmaceuticals, Inc.,

Debtor.

Chapter 11

Case No. 25-____ (____)

**CORPORATE OWNERSHIP STATEMENT PURSUANT TO FEDERAL RULES OF
BANKRUPTCY PROCEDURE 1007 AND 7007.1**

Pursuant to rules 1007(a)(1) and 7007.1 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), Apertor Pharmaceuticals, Inc., as proposed debtor and debtor in possession (the “Debtor”) respectfully represents that, as of December 12, 2025, the following are corporations that own 10 percent or more of equity interest in the Debtor:

Entity	Percentage of Equity Interest¹
ATP Life Science Ventures, L.P.	84.5%

¹ The Equity Interests disclosed are reflected on a fully diluted basis.

Fill in this information to identify the case:Debtor name Apertor Pharmaceuticals, Inc.United States Bankruptcy Court for the: DISTRICT OF DELAWARE

Case number (if known) _____

☐ Check if this is an amended filing

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- ☐ *Schedule A/B: Assets—Real and Personal Property* (Official Form 206A/B)
- ☐ *Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- ☐ *Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- ☐ *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- ☐ *Schedule H: Codebtors* (Official Form 206H)
- ☐ *Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- ☐ *Amended Schedule*
- ☒ *Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders* (Official Form 204)
- ☒ Other document that requires a declaration **Corporate Ownership Statement (Rule 7007.1)**

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 12/15/2025**x /s/ Edmund Graziani**

Signature of individual signing on behalf of debtor

Edmund Graziani

Printed name

CEO

Position or relationship to debtor